Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics (INKT) filed a Form 144 proposing the sale of 786,750 shares of common stock, with an aggregate market value of $12,572,265, to be sold approximately on 08/29/2025 on the INKT exchange. The filing states these shares were originally issued on 07/05/2017 in an original issuance from the issuer when it was a wholly owned subsidiary of Agenus Inc.; the shares were acquired in exchange for Agenus Inc.'s initial capital contribution. The filer reports no securities sold in the past three months and provides the standard representation that no undisclosed material adverse information is known.
The company may offer and sell up to an additional $36,585,515 of common stock through its at-the-market program under this updated prospectus supplement. This follows prior sales of 478,462 shares for gross proceeds of $13,414,485 under the same sales agreement with B. Riley Securities as sales agent.
The company’s public float was about $98.8 million, based on 1,539,804 shares of common stock held by non‑affiliates as of August 12, 2025, at a reference price of $64.17 per share. Because the public float now exceeds $75 million, the company is no longer subject to the Form S‑3 General Instruction I.B.6 sales limitations for this registration.
MiNK Therapeutics, Inc. filed a Form S-8 registration statement to register additional shares for its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The company states this filing does not involve a capital-raising transaction, a public offering, or a current issuance of shares. Any shares covered may be delivered only in connection with awards or purchases under these plans in accordance with their terms. The filing incorporates by reference three prior effective S-8 registrations for the same plans and includes standard exhibits such as organizational documents, plan documents, legal opinions, auditor consent, and powers of attorney.
MiNK Therapeutics (INKT) reported operational and financing updates in its Form 10-Q. The company completed an Option Exchange that re-priced 647,915 options to an exercise price of $7.43 with a 10-year term and unchanged vesting, producing approximately $0.6 million of incremental share-based compensation expense ($0.4 million recognized immediately and $0.2 million over the remaining vesting period). Agenus-related intercompany activities are disclosed, including a $14.5 million note receivable as of June 30, 2025 that Agenus agreed not to require repayment for the foreseeable future; interest accrues and may convert at Agenus’ election into equity at 80% of a qualified financing price. The company completed a 1-for-10 reverse stock split effective January 28, 2025. Nasdaq compliance for Minimum Value of Listed Securities was restored after MVLS exceeded $35.0 million for the required consecutive period. Clinical highlights include a durable complete remission in a refractory metastatic testicular cancer patient and a durable partial response in an advanced gastric cancer patient following agenT-797 plus checkpoint blockade.
MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing states that the information under Item 2.02 and Exhibit 99.1 is being furnished and therefore is not intended to be deemed filed for purposes of Section 18 of the Exchange Act. The 8-K itself does not include the underlying financial figures; the press release referenced in Exhibit 99.1 contains the detailed results and the Cover Page Interactive Data File is included as Exhibit 104.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K announcing that on 15 July 2025 it entered into an At-Market Issuance Sales Agreement with B. Riley Securities. The agreement allows the company to issue and sell up to $50 million of common stock from time to time on the open market.
The shares will be offered under the company’s effective Form S-3 shelf registration (File No. 333-268143) via a base prospectus (dated 8 Nov 2022) and a new prospectus supplement dated 15 July 2025. Sales will be made at prevailing market prices, with B. Riley acting as the agent for placement; compensation terms were not disclosed in this filing.
Exhibits include: (1) the full Sales Agreement (Ex 1.1); (2) the legal opinion and consent of Latham & Watkins LLP (Ex 5.1 & 23.1); and (3) the cover-page Inline XBRL file (Ex 104).
Key Implications for Investors
- The facility provides flexible, immediate access to capital that can support R&D, clinical trials or general corporate purposes without negotiating separate financing rounds.
- Issuances will be executed “at-the-market,” potentially creating incremental selling pressure and dilution as shares are sold into the market.
- The $50 million capacity should be evaluated relative to MiNK’s market capitalisation; if sizeable, ongoing issuance could materially increase the share count.
MiNK Therapeutics, Inc. (Nasdaq: INKT) filed an 8-K to highlight new clinical evidence supporting its allogeneic invariant natural killer T-cell therapy, agenT-797.
- Landmark peer-reviewed case: Nature’s Oncogene published a complete, durable remission (>2 years) in a patient with metastatic, treatment-refractory testicular cancer after a single agenT-797 infusion plus nivolumab (trial NCT05108623). No CRS or GVHD observed; donor iNKT cells persisted up to six months.
- Phase 2 gastric cancer signals: At the 2025 AACR Immuno-Oncology meeting, MiNK reported immune activation, increased tumor infiltration and early tumour-control signals in second-line gastric cancer patients previously refractory to checkpoint inhibitors; several patients lived >12 months post-treatment.
- Additional case report: A separate Oncogene paper detailed a metastatic gastric cancer patient who achieved a 42 % tumour reduction and >9 months progression-free survival following a single agenT-797 dose with nivolumab.
- Pipeline momentum: The ongoing Phase 2 gastric cancer study (NCT06251973) is actively enrolling, with further read-outs expected “in upcoming months.”
The filing contains forward-looking statements and reminds investors of risk factors detailed in MiNK’s March 31 2025 10-Q.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K summarizing the results of its Annual Meeting of Stockholders held on 18 June 2025. A quorum was achieved with 2,793,022 shares (70.41% of outstanding) present in person or by proxy. Shareholders voted on three routine proposals outlined in the proxy dated 30 April 2025.
Proposal 1 – Election of Class I Directors: Incumbents Jennifer Buell and Ulf Wiinberg were each re-elected to serve until the 2028 meeting. Support levels were strong, with Buell receiving 2,337,073 “For” votes (98.7% of votes cast, excluding non-votes) and Wiinberg receiving 2,312,077 “For” votes (97.7%). Broker non-votes totaled 424,803 shares.
Proposal 2 – Option Exchange: Shareholders approved the company’s option exchange program, designed to allow eligible employees to exchange existing stock options for new options. The measure passed with 2,269,364 “For”, 97,538 “Against,” and 1,317 “Abstain,” while 424,803 broker non-votes were recorded.
Proposal 3 – Auditor Ratification: KPMG LLP was ratified as independent registered public accounting firm for fiscal 2025, receiving 2,773,188 “For” votes (99.1%), 12,846 “Against,” and 6,988 abstentions.
No other matters were brought before the meeting, and there were no disclosures regarding financial performance, strategic transactions, or changes in control. The filing is primarily procedural, confirming continued shareholder support for existing leadership and governance practices.